EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD

Rafał Bieś, Joanna Fojcik, Anna Warchala, Beata Trędzbor, Krzysztof Krysta iD, Katarzyna Piekarska-Bugiel, Marek Krzystanek iD

Pharmaceuticals · 13.09.2023 · 16 (9) · 1292

DOI: 10.3390/ph16091292 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 13.09.2023. Verfasst von Rafał Bieś und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Students' Association, Department and Clinic of Psychiatric Rehabilitation, Faculty of Medical Sciences, Medical University of Silesia, Zioło…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders. It was once thought to be a disorder affecting only children, but in those undiagnosed in childhood, symptoms do not disappear with age. There is now a growing recognition of the late diagnosis and treatment of adults with ADHD. The first-line drug in pharmacotherapy is methylphenidate, and information about its adverse effects, when used by adults, has not been as extensively described as in children. The aim of this article was to review the literature describing the risks of methylphenidate therapy for adults with ADHD. A total of 19 articles—15 clinical trials and 4 case reports presenting rare side effects resulting from methylphenidate therapy, such as reversible ischemic stroke, myocardial infarction, and psychotic episodes, were analyzed. The analysis from clinical trials included 3458 adult patients with ADHD and described the most common side effects, psychiatric adverse events, effects of methylphenidate treatment on sleep, laboratory results, body mass, and cardiovascular symptoms. Methylphenidate treatment is well tolerated, with side effects described, according to severity, as mild to moderate. We conclude that pharmacotherapy is not risk-free and methylphenidate, due to its side effects, may not be the first drug of choice for every patient.

Schlagwörter

Stichwörter der Autor:innen

ADHDadultsadverse effectsmethylphenidateneurodevelopmental disorderspsychostimulantsserious adverse eventstreatment risk

Autor:innen und Institutionen

  • Medical Students' Association, Department and Clinic of Psychiatric Rehabilitation, Faculty of Medical Sciences, Medical University of Silesia, Ziołowa 45/47, 40-635 Katowice, Poland.
  • Department of Psychiatric Rehabilitation, Leszek Giec Upper-Silesian Medical Centre, Medical University of Silesia, Ziołowa 45/47, 40-635 Katowice, Poland.
  • Department and Clinic of Psychiatric Rehabilitation, Faculty of Medical Sciences, Medical University of Silesia, Ziołowa 45/47, 40-635 Katowice, Poland.

ORCID-Profile: Krzysztof Krysta, Marek Krzystanek

Förderung

  • Medical University of Silesia

Zitieren

APA

Bieś, R., Fojcik, J., Warchala, A., Trędzbor, B., Krysta, K., Piekarska-Bugiel, K., & Krzystanek, M. (2023). The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD. Pharmaceuticals, 16(9), 1292. https://doi.org/10.3390/ph16091292

Vancouver

Bieś R, Fojcik J, Warchala A, Trędzbor B, Krysta K, Piekarska-Bugiel K, et al. The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD. Pharmaceuticals. 2023;16(9):1292. doi:10.3390/ph16091292

BibTeX
@article{Bie2023,
  author = {Bieś, Rafał and Fojcik, Joanna and Warchala, Anna and Trędzbor, Beata and Krysta, Krzysztof and Piekarska-Bugiel, Katarzyna and Krzystanek, Marek},
  title = {The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {9},
  pages = {1292},
  doi = {10.3390/ph16091292}
}
Kostenlos starten →